ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
5,942.47
1.26%
US Tech 100
20,762.73
1.73%
Dow Jones
42,732.13
0.80%
Brent Oil
76.495
0.00%
Bitcoin
97,990.00
-0.22%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NYSE
  6. Organon and Co (OGN)

  7. Organon and Co (OGN) News

OGN

Organon (OGN)

Organon and Co
Date:
Sort by:
 Showing the most relevant articles for your search:NYSE:OGN
DateTimeSourceHeadlineSymbolCompany
12/23/20246:01AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
12/19/20247:30AMBusiness WireOrganon To Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNYSE:OGNOrganon and Co
12/16/20247:30AMBusiness WireFDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
12/06/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
11/05/20247:40AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
11/05/20247:29AMBusiness WireUpdate on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and OlderNYSE:OGNOrganon and Co
11/01/20248:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:OGNOrganon and Co
10/31/20248:40AMBusiness Wire米国FDAが、PROLIA/XGEVA（デノスマブ）のバイオシミラー候補HLX14の生物学的製剤承認申請（BLA）を受理NYSE:OGNOrganon and Co
10/31/20248:39AMBusiness WireUS-amerikanische FDA akzeptiert BLA für HLX14 – den Biosimilar-Kandidat zu PROLIA/XGEVA (Denosumab)NYSE:OGNOrganon and Co
10/31/20248:39AMBusiness Wire美國FDA接受PROLIA/XGEVA（地諾單抗）生物學名藥候選藥物HLX14的生物製品授權申請(BLA)NYSE:OGNOrganon and Co
10/31/20248:00AMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
10/31/20247:30AMBusiness WireOrganon Reports Results for the Third Quarter Ended September 30, 2024NYSE:OGNOrganon and Co
10/31/202412:02AMBusiness WireLa FDA des États-Unis accepte la demande de licence de produits biologiques (BLA) pour HLX14, le candidat biosimilaire de PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
10/30/20246:00AMBusiness WireUS FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)NYSE:OGNOrganon and Co
10/29/202412:22PMBusiness WireOrganon vollzieht Übernahme von Dermavant einschließlich der innovativen dermatologischen Therapie VTAMA® (Tapinarof) Creme, 1 %NYSE:OGNOrganon and Co
10/29/202412:22PMBusiness Wireオルガノン、ダーマバントの買収を完了し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1％を取得NYSE:OGNOrganon and Co
10/29/202412:22PMBusiness WireOrganon conclut l'acquisition de Dermavant, qui propose notamment un traitement dermatologique innovant : la crème VTAMA® (tapinarof) 1 %NYSE:OGNOrganon and Co
10/28/20249:25AMBusiness WireOrganon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
10/28/20249:25AMGlobeNewswire Inc.Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%NYSE:OGNOrganon and Co
10/09/20247:30AMBusiness WireOrganon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024NYSE:OGNOrganon and Co
10/08/20248:01AMPR Newswire (Canada)Organon Canada Promotes Geneviève Gauthier as Executive Director, Corporate Affairs and Community Engagement and Appoints Jeffrey Malawski as Executive Director, Women's Health and Established BrandsNYSE:OGNOrganon and Co
10/08/20248:01AMPR Newswire (Canada)Organon Canada promeut Geneviève Gauthier au poste de directrice exécutive, Affaires corporatives et Engagement communautaire, et nomme Jeffrey Malawski comme directeur exécutif, Santé des femmes et marques établiesNYSE:OGNOrganon and Co
09/30/20243:26PMBusiness Wireパージェタ（Perjeta®）（ペルツズマブ）バイオシミラー候補HLX11の第3相比較臨床試験で主要評価項目を達成NYSE:OGNOrganon and Co
09/30/202412:17PMBusiness WirePrimärer Endpunkt in Phase-3-Vergleichsstudie zu Perjeta® (Pertuzumab) Biosimilar-Kandidat HLX11 erreichtNYSE:OGNOrganon and Co
09/30/202411:59AMBusiness WireCritères principal atteint dans une étude clinique comparative de phase 3 sur le candidat biosimilaire HLX11 du Perjeta® (pertuzumab)NYSE:OGNOrganon and Co
09/30/20246:00AMBusiness WirePrimary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11NYSE:OGNOrganon and Co
09/26/20249:50AMPR Newswire (Canada)Organon Canada and the Alberta Women's Health Foundation unite to raise awareness and advocate for universal access to contraception in CanadaNYSE:OGNOrganon and Co
09/26/20249:49AMPR Newswire (Canada)Organon Canada et l'Alberta Women's Health Foundation s'unissent pour accroître la sensibilisation et prôner l'accès universel à la contraception au CanadaNYSE:OGNOrganon and Co
09/23/20244:21PMEdgar (US Regulatory)Form 8-K - Current reportNYSE:OGNOrganon and Co
09/19/20242:30PMBusiness WireオルガノンがDermavantを買収し、画期的な皮膚科治療薬VTAMA®（タピナロフ）クリーム1%を取得NYSE:OGNOrganon and Co
 Showing the most relevant articles for your search:NYSE:OGN

Your Recent History

USOTC
AZRH
Azure (PK)
USOTC
GDVM
Global Developments (PK)
USOTC
TWOH
Two Hands (PK)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
RDGL
Vivos (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
COIN
XRPUSD
Ripple
NASDAQ
TSLA
Tesla
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
FNMA
Fannie Mae (QB)
USOTC
HMBL
HUMBL (PK)
USOTC
RNVA
Rennova Health (CE)
NASDAQ
AMRN
Amarin
USOTC
WDLF
Decentral Life (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
NASDAQ
LWLG
Lightwave Logic
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads